Lexicon Pharmaceuticals, Inc. - LXRX Total Company Value-to-Revenue Ratio

lexpharma.com (LXRX) - corporate logo

Lexicon Pharmaceuticals (LXRX) is developing the commercial potential of sotagliflozin, expanding its cardiology pipeline. Reviewing the EV/Sales trajectory on GURU.Markets, it is evident that the parameter value is 16084.07, which assesses the value of the operating model. Success depends on physician adoption of the therapy and marketing, while protection against market behemoths is ensured by unique FDA patents on protein inhibition.

LXRX Lexicon Pharmaceuticals: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

lexpharma.com - analytical breakdowns and key metrics (LXRX)

Fundamental valuation:Lexicon Pharmaceuticals, LXRX
Flagship merchandise of Lexicon Pharmaceuticals

This indicator allows for an assessment of the market value of Lexicon Pharmaceuticals (LXRX) by accounting for net debt relative to generated revenue streams. By analyzing the EV/Sales ratio, an investor can see the business value stripped of leverage influence. The current value of 16084.07 reflects market expectations regarding the commercialization of the drug Inpefa. The company's strong pricing power, driven by the uniqueness of SGLT1/SGLT2 inhibitors, justifies the premium nature of this metric. The trend of this indicator helps to timely identify overvalued stock prices.

Competitor analysis for Lexicon Pharmaceuticals

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)